SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the presentation of positive safety and bi...

• Multi-Target Collaboration Leverages Vividion's Screening Platform to Discover and Develop Highly Selective Small Molecules for E3 Ligases and Select Oncology and Immunology Targets

• Vividion Receives $135 Million Upfront Payment With Potential for Multi-Billion Dollar Future Payments

SAN DIEGO,...

• Alpha-1 Antitrypsin Deficiency Program Demonstrates More than Four-Fold Increase in Circulating Levels of Functional Protein Following Durable Direct Correction In Vivo

• Novel HbG-Makassar Program for Sickle Cell Disease Demonstrates Direct Correction Levels Greater than 80% with Corresponding HbS...

SAN DIEGO, April 30, 2020 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., today announced that preliminary results from an independent preclinical study showed that oncology product candidate zotatifin (eFT226) had in vitro antiviral activity against SARS-CoV-2, the virus that causes COVID-19. The result...

Study Presented in Virtual Session at AACR Annual Meeting Provides Evidence of Potential for Zotatifin to Drug an Important Class of Oncogene Drivers

SAN DIEGO, April 27, 2020 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors (STRIs)...

Vir's has two candidates that have proved highly potent in neutralising SARS-CoV-2 in live virus-cellular assays

GlaxoSmithKline PLC (LON:GSK) is to invest US$250mln into Nasdaq-listed Vir Biotechnology Inc (NASDAQ:VIR), with the two companies to work together on potential treatments for coronavirus.

It is...

San Francisco-based Vir Biotechnology indicated it has identified several human monoclonal antibody (mAb) candidates against SARS-CoV-2, the virus causing COVID-19. In the interest of saving time, the company’s lead development was transferred to WuXi Biologics and Biogen several weeks ago with human tria...

-- Research Collaboration to Develop Next Generation Cell-based Therapies for Solid Tumors --

-- $40 Million Raised by CERo to Facilitate Preclinical and Clinical Development --

SOUTH SAN FRANCISCO, Calif., March 18, 2020 (GLOBE NEWSWIRE) -- CERo Therapeutics, Inc., a privately held biopharmaceutical compan...

Xconomy Boston — Gene editing biotech Beam Therapeutics raised $180 million in its initial public offering Wednesday after offering 48 percent more shares than it initially anticipated.

Beam, which was slated to begin trading Thursday on the Nasdaq exchange under the stock symbol “BEAM,” sold 9.25 million...

SAN DIEGO, Jan. 09, 2020 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, and Pfizer Inc. (NYSE: PFE) today announced an exclusive worldwide license and collaboration agreement to develop small-molecule inhi...